Preoperative plasma levels of transforming growth factor beta1 (TGF-β1 strongly predict progression in patients undergoing radical prostatectomy

Journal of Clinical Oncology

Volumn 19, Issue 11, 2001, Pages 2856-2864

  Shariat, S F ^a   Shalev, M ^a   Menesses Diaz, A ^a   Kim, I Y ^a   Kattan, M W ^a   Wheeler, T M ^a   Slawin, K M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER SURGERY; CONTROLLED STUDY; CORRELATION FUNCTION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL ANALYSIS;

EID: 0035367931     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.11.2856     Document Type: Article

References (53)

1. Temporal trends in rates of prostate cancer: Declining incidence of advanced stage disease, 1974 to 1994
2. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening
3. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control
4. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
5. Preoperative assessment of prostatic carcinoma by computerized tomography: Weaknesses and new perspectives
6. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update
7. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
8. Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix
9. Production and significance of TGF-beta in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma
10. Transforming growth factor-beta 1 overproduction in prostate cancer: Effects on growth in vivo and in vitro
11. Transforming growth factor-beta 1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer
12. Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study
13. Transforming growth factor beta 1 as a biomarker for prostate cancer
14. Tissue expression of transforming growth factor beta1 and its receptors: Correlation with pathologic parameters and progression in patients undergoing radical prostatectomy
15. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer
16. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma
17. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma: Comparison with chronic liver diseases
18. Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma
19. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma
20. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer
21. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma
22. Elevation of serum transforming growth factor beta 1 level in patients with metastatic prostate cancer
23. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases
24. Transforming growth factor beta as a clinical biomarker for prostate cancer
25. Longitudinal screening for prostate cancer with prostate-specific antigen
26. Fresh tissue harvest for research from prostatectomy specimens
27. Observations on the doubling time of prostate cancer: The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
28. The influence of pathological parameters of positive surgical margins on prognosis in patients undergoing radical prostatectomy
29. Disease progression following radical prostatectomy in men with Gleason score 7 tumor
30. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer
31. Adenocarcinoma of the prostate invading the seminal vesicle: Prognostic stratification based on pathologic parameters
32. Radical prostatectomy for clinical stage T1 and T2 prostate cancer
33. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results
34. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years
35. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
36. Anatomic considerations in carcinoma of the prostate
37. Prognostic significance of positive surgical margins in radical prostatectomy specimens
38. Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension
39. Prediction of progression following radical prostatectomy: A multivariate analysis of 721 men with long-term follow-up
40. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy
41. Natural history of progression after PSA elevation following radical prostatectomy
42. National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening
43. Serum PSA after anatomic radical prostatectomy: The Johns Hopkins experience after 10 years
44. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage Tl-2 prostate cancer
45. Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay
46. Radical prostatectomy: Does higher volume lead to better quality?
47. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers
48. Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure
49. Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro
50. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone
51. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate
52. RT-PCR for PSA and hK2: Implications for staging and patient management in men undergoing radical prostatectomy
53. Genetic events and the role of TGF beta in epithelial tumour progression